Back to News
Market Impact: 0.15
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Source: globenewswire.com
Healthcare & BiotechCorporate Earnings
An investor webcast is scheduled for 4:30 p.m. ET on October 22 to discuss Q3 2026 financial results and final efficacy results from the ORIGIN 3 study of TRUTAKNA (atacicept-vymj). The final efficacy results are slated for a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026; the article provides no efficacy data or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Elon Musk says SpaceX and Tesla exploring largest merger in history
- Asia stocks rebound as SpaceX, Super Micro results lift chipmakers
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Capital One's strong quarter and progressing Discover integration are rewarded on Wall Street
- Tesla supplier CATL shares plunge after disappointing Q3 results
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Family Offices: A Stack by Decision Type
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs